The first combination treatment for patients with hyperuricemia associated with gout has received FDA approval. Specifically, the new medication is indicated for patients who haven’t achieved target serum uric acid levels with allopurinol alone.
Marketed as Duzallo, the new oral medication combines allopurinol, a xanthine oxidase inhibitor, with lesinurad, a selective uric acid reabsorption inhibitor that was approved in 2015. Together they address both underlying causes of hyperuricemia—overproduction and inefficient excretion of serum uric acid. The medication will be available in combinations of 200 mg of lesinurad plus 300 mg of allopurinol and 200 mg of each drug.
Voelker R. Combination Drug Approved for Gout. JAMA. 2017;318(13):1214. doi:10.1001/jama.2017.13878
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.